Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2146969
Max Phase: Preclinical
Molecular Formula: C66H100N14O10
Molecular Weight: 1249.61
Molecule Type: Small molecule
Associated Items:
ID: ALA2146969
Max Phase: Preclinical
Molecular Formula: C66H100N14O10
Molecular Weight: 1249.61
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)(C)[C@@H]1NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC(=O)[C@H](C23CC4CC(CC(C4)C2)C3)NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC1=O
Standard InChI: InChI=1S/C66H100N14O10/c1-65(2,3)53-61(87)73-45(20-10-26-67)55(81)75-49(35-40-16-6-4-7-17-40)63(89)80-31-15-25-52(80)60(86)72-48(23-13-29-70)58(84)78-54(66-37-42-32-43(38-66)34-44(33-42)39-66)62(88)74-46(21-11-27-68)56(82)76-50(36-41-18-8-5-9-19-41)64(90)79-30-14-24-51(79)59(85)71-47(22-12-28-69)57(83)77-53/h4-9,16-19,42-54H,10-15,20-39,67-70H2,1-3H3,(H,71,85)(H,72,86)(H,73,87)(H,74,88)(H,75,81)(H,76,82)(H,77,83)(H,78,84)/t42?,43?,44?,45-,46-,47-,48-,49+,50+,51-,52-,53+,54+,66?/m0/s1
Standard InChI Key: AULOTTGMOQIHAQ-HANYKBMQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1249.61 | Molecular Weight (Monoisotopic): 1248.7747 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kapoerchan VV, Knijnenburg AD, Keizer P, Spalburg E, de Neeling AJ, Mars-Groenendijk RH, Noort D, Otero JM, Llamas-Saiz AL, van Raaij MJ, van der Marel GA, Overkleeft HS, Overhand M.. (2012) 'Inverted' analogs of the antibiotic gramicidin S with an improved biological profile., 20 (20): [PMID:22989907] [10.1016/j.bmc.2012.08.038] |
Source(1):